Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelhardt

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 12, 2021
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry <i>N</i>-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6Thomas A Zanardi, Birgit Korbmacher, Laura Boone, et al.
Carcinogenesis|June 1, 1992
Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986K K Richardson, L M Helvering, D M Copple, et al.
Cancer Letters|July 30, 1993
Expression of TRPM-2 during involution and regeneration of the rat liverL M Helvering, K K Richardson, D M Horn, et al.
Regulatory Toxicology and Pharmacology : RTP|November 23, 2024
Carcinogenicity assessment of inotersen in Tg.rasH2 mice and Sprague-Dawley rats: Implications for 2'-MOE antisense oligonucleotidesTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Toxicologic Pathology|June 8, 2002
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safetyJohn L Vahle, Masahiko Sato, Gerald G Long, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1995
The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseC Ahgren, K Backro, F W Bell, et al.
Toxicologic Pathology|February 28, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. BiotherapeuticsKendall S Frazier, Jeffery A Engelhardt, Pierluigi Fant, et al.
Toxicologic Pathology|February 27, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense OligonucleotidesJeffery A Engelhardt, Pierluigi Fant, Silvia Guionaud, et al.
Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health|April 25, 2006
A virological survey in migrating waders and other waterfowl in one of the most important resting sites of GermanyA Hlinak, R U Mühle, O Werner, et al.
Toxicologic Pathology|December 27, 2018
Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 MiceTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
The Journal of Pharmacology and Experimental Therapeutics|January 12, 2021
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry <i>N</i>-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6Thomas A Zanardi, Birgit Korbmacher, Laura Boone, et al.
Carcinogenesis|June 1, 1992
Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986K K Richardson, L M Helvering, D M Copple, et al.
Cancer Letters|July 30, 1993
Expression of TRPM-2 during involution and regeneration of the rat liverL M Helvering, K K Richardson, D M Horn, et al.
Regulatory Toxicology and Pharmacology : RTP|November 23, 2024
Carcinogenicity assessment of inotersen in Tg.rasH2 mice and Sprague-Dawley rats: Implications for 2'-MOE antisense oligonucleotidesTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Toxicologic Pathology|June 8, 2002
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safetyJohn L Vahle, Masahiko Sato, Gerald G Long, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1995
The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseC Ahgren, K Backro, F W Bell, et al.
Toxicologic Pathology|February 28, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. BiotherapeuticsKendall S Frazier, Jeffery A Engelhardt, Pierluigi Fant, et al.
Toxicologic Pathology|February 27, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense OligonucleotidesJeffery A Engelhardt, Pierluigi Fant, Silvia Guionaud, et al.
Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health|April 25, 2006
A virological survey in migrating waders and other waterfowl in one of the most important resting sites of GermanyA Hlinak, R U Mühle, O Werner, et al.
Toxicologic Pathology|December 27, 2018
Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 MiceTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Pageof 16